Search Bar & Filters
Found 28 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatment options for people living with HIV-1, focusing on improving the current standard of care. The study compares a new once-weekly antiretroviral therapy ART combining islatravir and ulonivirine to the standard daily ART regimen, which includes multiple medications taken up to twice a day. This research aims to evaluate if the new study ART works as well as the current standard treatment, while also assessing its safety and how well participants tolerate it. Participants will be randomly assigned to one of several groups one group will receive the study drugs islatravir and ulonivirine once weekly, another will take the standard ART daily, and two additional groups will receive combinations of study drugs and placebos for 96 weeks. The study involves both phase 2 and phase 3 parts, with participants taking their assigned medication orally either once daily or once weekly during this period. Throughout the study, participants will attend regular visits for up to 96 weeks where researchers will monitor their HIV-1 RNA levels, CD4 T-cell counts, body weight, and any adverse events. The main measurement is the percentage of participants with HIV-1 RNA below 50 copiesmL at weeks 24 and 48 for phase 2 and phase 3 respectively. Safety and tolerability will also be closely observed, including any discontinuation due to adverse events. Participants health will be followed through various laboratory tests and assessments during the study period.
Actively Recruiting
Researchers are evaluating a new medication called VH4524184 for treating adults with HIV-1 who have never received treatment before. This Phase 2b study compares two doses of VH4524184, each taken with the medications emtricitabine and tenofovir alafenamide FTCTAF, against a standard HIV treatment combining dolutegravir and lamivudine DTG3TC. The goal is to collect long-term data on the antiviral activity of VH4524184 and to understand the best dosing for future studies. Participants are assigned to one of several groups one group receives a low dose of VH4524184 plus FTCTAF daily for 12 months, another group receives a high dose of VH4524184 plus FTCTAF daily for 12 months, and a third group takes DTG and 3TC daily for 24 months. After 12 months, those on VH4524184 may continue with a selected dose combined with FTCTAF daily until month 24. All medications are taken orally. During the study, participants attend scheduled visits for assessments including blood tests to measure HIV-1 RNA levels, CD4 T-cell counts, and drug concentrations. Researchers monitor the percentage of participants achieving viral suppression at 12 months and maintain it through 24 months. Safety is closely observed through tracking adverse events until roughly month 36. The total participation time may span up to 36 months to evaluate the long-term effects and safety of the treatments.
Actively Recruiting
Researchers are evaluating how the study medicine CagriSema helps adults living with obesity, with or without type 2 diabetes, lose weight. This clinical trial compares two different doses of CagriSema with semaglutide, a medicine already prescribed for weight loss. The study aims to understand the safety and effectiveness of CagriSema in reducing body weight over time. Participants are randomly assigned to receive one of three treatments CagriSema at dose level 1, CagriSema at dose level 2, or semaglutide. Each treatment is given once weekly as a subcutaneous injection over a 72-week period. The study lasts about 83 weeks in total to include all treatment and follow-up time. During the study, participants will have regular visits for assessments including body weight, body mass index, waist circumference, cholesterol levels, and blood sugar control. Questionnaires on physical function and quality of life will also be completed. Researchers will track any side effects and serious adverse events throughout the study and after treatment ends, monitoring safety for up to 80 weeks.
Actively Recruiting
Researchers are evaluating BG-C477, a targeted antibody-drug conjugate, in adults with advanced solid tumors that cannot be removed by surgery or have spread to other parts of the body. This Phase 1ab study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and early antitumor activity of BG-C477 alone and in combination with other anticancer agents. BG-C477 targets a protein called CEA on lung cancer cells to deliver a drug that prevents cancer cell multiplication and causes cell death. The study includes two parts Phase 1a tests increasing doses of BG-C477 alone to find a safe dose without serious side effects. Phase 1b evaluates the selected dose further, either alone or combined with chemotherapy or tislelizumab. BG-C477 is administered intravenously. Participants receive treatment during these phases, with sequential dose escalation and expansion cohorts. The treatment duration is about 9 months for Phase 1a and approximately 18 months for Phase 1b. Participants will attend regular clinic visits for treatment administration, health assessments, blood tests, tumor evaluations, and imaging studies. Researchers will monitor adverse events, determine the recommended dose levels, and assess tumor response and progression using standardized criteria. Safety and pharmacokinetic data will be collected up to about two years after the last dose. Overall participation lasts up to 18 months depending on the study phase.
Actively Recruiting
Researchers are evaluating the effectiveness of switching to the study drugs GS-3242 combined with Lenacapavir LEN compared to continuing the standard treatment Biktarvy bictegraviremtricitabinetenofovir alafenamide, BFTAF in adults with HIV-1 infection who are virologically suppressed. This Phase 2 randomized study aims to assess the safety and efficacy of an injectable regimen of GS-3242 plus LEN versus oral BFTAF in different treatment groups over distinct time points, with Part A focusing on Week 35 and Part B on Week 26. Participants are randomly assigned to receive either oral loading doses of GS-3242 and LEN tablets followed by intramuscular IM injections of these drugs for up to 52 weeks, or to continue daily oral BFTAF for the same duration. Different dosing regimens of GS-3242 and LEN are used across groups, with some groups receiving different IM doses. The study includes both randomized and non-randomized groups across the two parts. During the study, participants will be monitored for viral load, specifically HIV-1 RNA levels, using the US FDA Snapshot Algorithm at Weeks 26, 35, and 52, as well as CD4 cell counts. Safety is assessed by recording treatment-emergent adverse events throughout the study period. Drug concentrations are also measured at specific weeks to evaluate pharmacokinetics. The total participant involvement can last up to 52 weeks, with regular assessments to evaluate treatment efficacy and safety.
Actively Recruiting
Researchers are evaluating the efficacy and safety of orforglipron in adults with overweight who are at risk of developing obesity-related complications such as type 2 diabetes, hypertension, and dyslipidemia, or progressing to class 1 obesity. The study is a phase 3, randomized, double-blind, placebo-controlled trial that aims to understand whether this oral medication can reduce these risks over a two-year period. Participants will be randomly assigned to one of three groups receiving orforglipron orally throughout, orforglipron followed by placebo, or placebo followed by orforglipron. The study involves daily oral administration of these medications. The trial includes a long-term treatment period lasting up to 104 weeks about two years, during which participants are monitored for weight changes and the onset of obesity-related health issues. Throughout the study, participants will undergo regular assessments including measurements of body weight, waist circumference, blood pressure, blood markers like glycated hemoglobin and triglycerides, and quality of life questionnaires. Researchers will also monitor the time to onset of obesity-related complications and pharmacokinetics of orforglipron at specified intervals. Safety and effectiveness will be tracked continuously, with the primary outcome being the time until the development of obesity-related complications or progression to class 1 obesity.
Actively Recruiting
Researchers are evaluating treatments for non-small cell lung cancer NSCLC in adults with a specific KRAS G12D gene mutation. NSCLC is a common lung cancer type, and when it worsens after initial chemotherapy and immune therapy, options are limited. This study aims to compare a new drug, setidegrasib, with the standard drug docetaxel to see which better controls cancer progression and survival. Participants receive either setidegrasib or docetaxel through intravenous infusion. Setidegrasib is given on days 1, 8, and 15 of each 21-day cycle, while docetaxel is given on day 1 of each cycle. Treatment continues until cancer worsens, side effects prevent further use, or other medical decisions stop treatment. Some on docetaxel may switch to setidegrasib if their cancer progresses. Tumor scans are done every 6 weeks in the first year and every 9 weeks afterwards. During the study, participants have regular safety checks and monitoring of their health. Researchers assess how long cancer stays controlled without worsening and overall survival. They also measure symptoms, tumor response, drug processing in the body, and side effects. After progression, follow-up calls occur every 12 weeks to check on the participants condition. The study may last up to about four years depending on the outcome measures.
Actively Recruiting
The trial investigates the safety and effectiveness of ruxolitinib cream in treating children with nonsegmental vitiligo, a condition causing loss of skin pigment. It is a Phase 3, randomized, double-blind study aimed at evaluating how well this topical treatment works in pediatric participants aged 2 to 11 years with limited body surface affected by vitiligo. Participants are randomly assigned to receive either ruxolitinib 1.5% cream or a matching vehicle cream, both applied twice daily as a thin film to the affected skin areas. The study measures improvements in facial and total body vitiligo using specific scoring indexes over 24 and 52 weeks. Participants must stop other vitiligo treatments during the trial and are monitored for safety throughout. Throughout the study, participants undergo assessments including evaluation of skin pigment improvement using Facial Vitiligo Area Scoring Index F-VASI and Total Body Vitiligo Area Scoring Index T-VASI. Safety is tracked by recording any adverse events up to 30 days after treatment. Pharmacokinetic tests measure drug concentration at multiple time points. The total study duration extends up to nearly four years, with ongoing follow-up to evaluate treatment effects and safety.
Actively Recruiting
Researchers are evaluating the safety and effects of the study medicine PF-07248144 combined with fulvestrant for treating hormone receptor-positive HR-positive, HER2-negative advanced or metastatic breast cancer. This study focuses on patients whose cancer has progressed after prior treatment with cyclin dependent kinase CDK 46 inhibitor-based therapy. HR-positive breast cancer cells grow in response to hormones like estrogen and progesterone, while HER2-negative cells have little or no HER2 protein, which affects cancer growth and spread. Participants are divided into two groups one receives PF-07248144 tablets daily at home in 28-day cycles along with fulvestrant injections given at the clinic. The other group receives everolimus tablets daily combined with the investigators choice of endocrine therapy, either exemestane tablets or fulvestrant injections. The study compares the safety and effects of PF-07248144 plus fulvestrant against these standard treatments. During the study, participants will have regular clinic visits for injections and monitoring. Researchers will assess disease progression and survival, measure tumor response, record any side effects, and perform laboratory tests including ECGs and drug level checks. The main outcome is progression-free survival, tracked for up to two years, while other safety and effectiveness measures will be followed for up to five years. Total participation may extend over several years depending on individual outcomes.
Actively Recruiting
Researchers are evaluating whether the drug PF-08046054 works better alone compared to the standard chemotherapy docetaxel in adults with non-small cell lung cancer NSCLC who have tumors expressing PD-L1 at 1% or higher. These participants have cancer that has spread in their body or cannot be removed by surgery or treated with radiation. All participants must have experienced disease progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted therapies if they have specific genetic mutations. Participants are randomly assigned to one of two groups. One group receives PF-08046054 through an intravenous IV infusion twice every 21-day cycle, while the other group receives docetaxel as an IV infusion once every 21 days. The study may last up to 5 years if the participants cancer responds to treatment. This phase 3 study compares the two therapies to understand their impact on survival and disease progression. During the study, participants will visit the clinic regularly to monitor their health and response to treatment. Researchers will measure overall survival and other outcomes such as progression-free survival, response rates, duration of response, and quality of life using questionnaires. Safety will also be monitored through adverse event evaluations. The study includes biomarker analysis using tumor tissue samples and tracks drug levels and immune responses over time.
1-10 of 28
1